GlobeNewswire by notified

Sanoma Corporation - Managers' Transactions

Share

Sanoma Corporation, Managers’ Transactions, 7 December 2023 at 9:00 EET

Sanoma Corporation - Managers' Transactions

___________________________________________
Person subject to the notification requirement
Name: Holding Manutas Oy
Position: Closely associated person
(X) Legal person (1):Person Discharging Managerial Responsibilities In Issuer
Name: Anna Herlin
Position: Member of the Board
Issuer: Sanoma Oyj
LEI: 743700XJC24THUPK0S03
Notification type: INITIAL NOTIFICATION
Reference number: 45422/5/6
____________________________________________
Transaction date: 2023-12-05
Venue: BEUP
Instrument type: SHARE
ISIN: FI0009007694
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 2494 Unit price: 6.92 EUR

Aggregated transactions (1):
Volume: 2494 Volume weighted average price: 6.92 EUR
____________________________________________
Transaction date: 2023-12-05
Venue: CEUX
Instrument type: SHARE
ISIN: FI0009007694
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 267 Unit price: 6.94 EUR

Aggregated transactions (1):
Volume: 267 Volume weighted average price: 6.94 EUR
____________________________________________
Transaction date: 2023-12-05
Venue: DHEL
Instrument type: SHARE
ISIN: FI0009007694
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 987 Unit price: 6.92 EUR
(2): Volume: 987 Unit price: 6.92 EUR
(3): Volume: 881 Unit price: 6.92 EUR
(4): Volume: 3619 Unit price: 6.955 EUR
(5): Volume: 987 Unit price: 6.955 EUR
(6): Volume: 500 Unit price: 6.965 EUR
(7): Volume: 1851 Unit price: 6.945 EUR

Aggregated transactions (7):
Volume: 9812 Volume weighted average price: 6.94344 EUR
____________________________________________
Transaction date: 2023-12-05
Venue: NASDAQ HELSINKI LTD (XHEL)
Instrument type: SHARE
ISIN: FI0009007694
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 826 Unit price: 6.94 EUR
(2): Volume: 2845 Unit price: 6.94 EUR

Aggregated transactions (2):
Volume: 3671 Volume weighted average price: 6.94 EUR
____________________________________________
Transaction date: 2023-12-05
Venue: XPAC
Instrument type: SHARE
ISIN: FI0009007694
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 5223 Unit price: 6.92 EUR
(2): Volume: 881 Unit price: 6.92 EUR
(3): Volume: 1540 Unit price: 6.92 EUR
(4): Volume: 3015 Unit price: 6.96 EUR
(5): Volume: 1316 Unit price: 6.96 EUR
(6): Volume: 3952 Unit price: 6.94 EUR
(7): Volume: 1146 Unit price: 6.94 EUR
(8): Volume: 1316 Unit price: 6.94 EUR
(9): Volume: 1526 Unit price: 6.92 EUR

Aggregated transactions (9):
Volume: 19915 Volume weighted average price: 6.93514 EUR
____________________________________________
Transaction date: 2023-12-05
Venue: POSIT (XPOS)
Instrument type: SHARE
ISIN: FI0009007694
Nature of transaction: ACQUISITION

Transaction details
(1): Volume: 1413 Unit price: 6.955 EUR
(2): Volume: 1041 Unit price: 6.92 EUR
(3): Volume: 1820 Unit price: 6.92 EUR
(4): Volume: 6640 Unit price: 6.92 EUR
(5): Volume: 2650 Unit price: 6.96 EUR
(6): Volume: 4620 Unit price: 6.96 EUR
(7): Volume: 2730 Unit price: 6.96 EUR
(8): Volume: 3563 Unit price: 6.96 EUR
(9): Volume: 3422 Unit price: 6.96 EUR
(10): Volume: 4398 Unit price: 6.96 EUR
(11): Volume: 4286 Unit price: 6.96 EUR
(12): Volume: 1316 Unit price: 6.96 EUR
(13): Volume: 3451 Unit price: 6.96 EUR
(14): Volume: 5233 Unit price: 6.94 EUR
(15): Volume: 6048 Unit price: 6.94 EUR
(16): Volume: 2049 Unit price: 6.955 EUR
(17): Volume: 7500 Unit price: 6.94 EUR
(18): Volume: 1354 Unit price: 6.94 EUR
(19): Volume: 2789 Unit price: 6.945 EUR
(20): Volume: 3172 Unit price: 6.945 EUR
(21): Volume: 2188 Unit price: 6.945 EUR
(22): Volume: 3785 Unit price: 6.94 EUR
(23): Volume: 1569 Unit price: 6.94 EUR
(24): Volume: 1804 Unit price: 6.92 EUR
(25): Volume: 2611 Unit price: 6.915 EUR
(26): Volume: 6788 Unit price: 6.915 EUR
(27): Volume: 601 Unit price: 6.915 EUR

Aggregated transactions (27):
Volume: 88841 Volume weighted average price: 6.94254 EUR


Sanoma 
Sanoma is an innovative and agile learning and media company impacting the lives of millions every day. Our Sustainability Strategy is designed to maximise our positive ‘brainprint’ on society and to minimise our environmental footprint. We are committed to the UN Sustainable Development Goals and signatory to the UN Global Compact.

Our learning products and services enable teachers to develop the talents of every child to reach their full potential. We offer printed and digital learning content as well as digital learning and teaching platforms for primary, secondary and vocational education, and want to grow our business.

Our Finnish media provide independent journalism and engaging entertainment also for generations to come. Our unique cross-media position offers the widest reach and tailored marketing solutions for our business partners.

Today, we operate in twelve European countries and employ more than 5,000 professionals. In 2022, our net sales amounted to approx. 1.3bn€ and our operational EBIT margin excl. PPA was 14.6%. Sanoma shares are listed on Nasdaq Helsinki. More information is available at sanoma.com.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria24.2.2024 15:51:43 CET | Press release

Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an oral BTK inhibitor, significantly reduced weekly itch severity score (ISS7) as early as the first week of treatment in adults with moderate to severe CSUData form the basis for the Phase 3 CSU and prurigo nodularis programs to start in 2024Pivotal Phase 3 readout in immune thrombocytopenia and Phase 2 readouts in asthma, IgG4-related disease and warm autoimmune hemolytic anemia expected in 2024Rilzabrutinib is one of 12 potential blockbusters in Sanofi’s leading immunology pipeline Paris, February 24, 2024. Positive results from the Phase 2 study RILECSU showed that rilzabrutinib significantly improved itch, hives and urticaria in adults with moderate-to-severe chronic spontaneous urticaria (CSU), whose symptoms are not adequately controlled by H1 antihistamines. These r

Application to delist from Nasdaq First North Growth Market Denmark submitted24.2.2024 14:17:57 CET | Press release

Copenhagen, Feb. 24, 2024 (GLOBE NEWSWIRE) -- Announcement no. 3-2024 Hypefactors has submitted an official application to delist from Nasdaq First North Growth Market Denmark. A decision backed by 98,42% of the share capital represented at the Extraordinary General Meeting held on 23. February 2024 Delisting requires the final approval from Nasdaq. The details of​ the delisting ​procedure and ​consequenses for shareholders is stated in the company announcement 01-2024. ---- About Hypefactors A/S Hypefactors is an AI based reputation and corporate trust technology company, providing a tech platform to support better media intelligence and reputation/trust management. Hypefactors combine data, analytics, technology, and tools to provide a unified and easy-to-use experience. With all the tools to automate and ease the work, and all the facts to document the results. In addition to media monitoring across the different media channels, the platform provides access to several facts, incl. a

798 Launches Folk Culture Sector of Square Art Festival, 110,000+ Visitors Reached During the Chinese New Year Vacation24.2.2024 03:00:00 CET | Press release

BEIJING, Feb. 24, 2024 (GLOBE NEWSWIRE) -- 798 Art District announces today that the Folk Culture Sector of the 798 Square Art Festival will launch on February 24, 2024, at the CONCERTED SQUARE of 798 Art District in Beijing. This sector aims to bridge contemporary art with urban and rural folk culture. Visiting 798 during the Lantern Festival, you can experience the power of contemporary art intertwined with traditional folk customs and enjoy the familiar yet strange world of Chinese local culture. Event Poster February 24 is the Lantern Festival in China, and it marks the end of the Chinese New Year festivities. The New Year vacation in 798 was full of lively atmosphere. Throughout the Spring Festival, 15 exhibitions were ongoing in 798, including the Joy Art Museum's "Joy in the Year of the Dragon", IOMA Art Center's "Dragon Roaming the World and Prospering", MOCUBE's "Upon Arrival of Dragon", and Le Rime Gallery's "Jia Chen Mountain Chronicle". Based on statistics, there were over

Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®24.2.2024 02:15:00 CET | Press release

SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and Teva in the U.S. market SIMLANDI will qualify for interchangeable exclusivity in the U.S. for some concentration strengths Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchangeable biosimilar to Humira, for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adul Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SIMLANDI (adalimumab-ryvk) injection, as an interchan

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons23.2.2024 23:50:47 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 23, 2024 –Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, this document discloses the data of the transactions made in Genmab A/S (Nasdaq: GMAB) by managerial employees and their closely associated persons. The company’s managerial employees and their closely associated persons have given Genmab A/S power of attorney on their behalf to publish trading in Genmab shares by the company’s managerial employees and their closely associated persons. Please find below a statement of such trading in shares issued by Genmab A/S 1.Details of the person discharging managerial responsibilities / person closely associateda)NameJan G. J. van de Winkel2.Reason for the notificationa)Position/statusPresident & Chief Executive Officerb)Initial notification/AmendmentInitial notification3.Details of the issuer, emission allowance market participant, auction platform,

HiddenA line styled icon from Orion Icon Library.Eye